Larvol Delta - Editorial-Comment-to-quotPrimary-Resistance-to-Immune-Checkpoint-Inhibitor-Combination-Therapy-in-Metastatic-Renal-Cell-Carcinoma-Focus-on-Nivolumab-Plus-Ipilimumabquot

Yervoy (ipilimumab) - BMS

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

http://www.ncbi.nlm.nih.gov/pubmed/42806790

Hiroshi Hirata

Sep 30, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next